Soft Tissue Allografts Market

Executive Summary

Soft Tissue Allografts Market was valued at US $3.96 billion in 2021 and is projected to grow at 5.83% CAGR over the forecast period to reach US $5.56 billion by 2027. Soft Tissue Allografts Market represented US $0.42 billion opportunity over 2019-2021 and estimated to create US $1.60 billion opportunity in 2027 over 2021.

Soft Tissue Allografts from Consainsights analyses the Soft Tissue Allografts Market in the Life Sciences industry over the forecast period to 2027.

Soft Tissue Allografts research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Soft Tissue Allografts segmentation includes Type, Application, End-User and Geography.

Based on the Type, the Soft Tissue Allografts analysis covers Cartilage Allograft, Tendon Allograft, Meniscus Allograft, Dental Allograft, Other Types.

In Type segment, Cartilage Allograft segment has highest cagr growth of 5.16%.

Based on the Application, the Soft Tissue Allografts analysis covers Orthopedic, Dentistry, Wound Care, Other Applications.

In Application segment, Orthopedic segment has highest cagr growth of 5.16%.

Based on the End-User, the Soft Tissue Allografts analysis covers Hospitals, Aesthetic Centres, Orthopedic Clinics, Dental Clinics, Other End Users.

In End-User segment, Hospitals segment has highest cagr growth of 5.16%.

Based on the region, the Soft Tissue Allografts analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include Abbvie inc. (Allergan), Conmed Corporation, Xtant Medical Holdings Inc., Bone Bank Allografts, Smith & Nephew(Osiris Therapeutics Inc.), Integra LifeSciences Corporation, Stryker Corporation, Zimmer Biomet, Arthrex Inc., Direct Biologics and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Type

Introduction

In 2021, Cartilage Allograft segment has the highest revenue of US $1.68 billion and is expected to grow at CAGR of 5.16% by 2027 Cartilage Allograft segment has highest cagr growth of 5.16%.

Cartilage Allograft

Cartilage Allograft segment was valued at US $1.50 billion in 2019 and is projected to grow at 5.16% CAGR over the forecast period to reach US $2.36 billion by 2027. Cartilage Allograft segment represented US $0.18 billion opportunity over 2019-2021 and estimated to create US $0.68 billion opportunity in 2027 over 2021.

Tendon Allograft

Tendon Allograft segment was valued at US $0.72 billion in 2019 and is projected to grow at 5.16% CAGR over the forecast period to reach US $1.14 billion by 2027. Tendon Allograft segment represented US $0.09 billion opportunity over 2019-2021 and estimated to create US $0.33 billion opportunity in 2027 over 2021.

Meniscus Allograft

Meniscus Allograft segment was valued at US $0.56 billion in 2019 and is projected to grow at 5.16% CAGR over the forecast period to reach US $0.88 billion by 2027. Meniscus Allograft segment represented US $0.07 billion opportunity over 2019-2021 and estimated to create US $0.25 billion opportunity in 2027 over 2021.

Dental Allograft

Dental Allograft segment was valued at US $0.47 billion in 2019 and is projected to grow at 5.16% CAGR over the forecast period to reach US $0.74 billion by 2027. Dental Allograft segment represented US $0.06 billion opportunity over 2019-2021 and estimated to create US $0.21 billion opportunity in 2027 over 2021.

Other Types

Other Types segment was valued at US $0.28 billion in 2019 and is projected to grow at 5.16% CAGR over the forecast period to reach US $0.44 billion by 2027. Other Types segment represented US $0.03 billion opportunity over 2019-2021 and estimated to create US $0.13 billion opportunity in 2027 over 2021.

Application

Introduction

In 2021, Orthopedic segment has the highest revenue of US $1.44 billion and is expected to grow at CAGR of 5.16% by 2027 Orthopedic segment has highest cagr growth of 5.16%.

Orthopedic

Orthopedic segment was valued at US $1.28 billion in 2019 and is projected to grow at 5.16% CAGR over the forecast period to reach US $2.02 billion by 2027. Orthopedic segment represented US $0.15 billion opportunity over 2019-2021 and estimated to create US $0.58 billion opportunity in 2027 over 2021.

Dentistry

Dentistry segment was valued at US $1.22 billion in 2019 and is projected to grow at 5.16% CAGR over the forecast period to reach US $1.92 billion by 2027. Dentistry segment represented US $0.15 billion opportunity over 2019-2021 and estimated to create US $0.55 billion opportunity in 2027 over 2021.

Wound Care

Wound Care segment was valued at US $0.81 billion in 2019 and is projected to grow at 5.16% CAGR over the forecast period to reach US $1.27 billion by 2027. Wound Care segment represented US $0.10 billion opportunity over 2019-2021 and estimated to create US $0.37 billion opportunity in 2027 over 2021.

Other Applications

Other Applications segment was valued at US $0.23 billion in 2019 and is projected to grow at 5.16% CAGR over the forecast period to reach US $0.36 billion by 2027. Other Applications segment represented US $0.03 billion opportunity over 2019-2021 and estimated to create US $0.10 billion opportunity in 2027 over 2021.

End-User

Introduction

In 2021, Hospitals segment has the highest revenue of US $1.71 billion and is expected to grow at CAGR of 5.16% by 2027 Hospitals segment has highest cagr growth of 5.16%.

Hospitals

Hospitals segment was valued at US $1.52 billion in 2019 and is projected to grow at 5.16% CAGR over the forecast period to reach US $2.40 billion by 2027. Hospitals segment represented US $0.18 billion opportunity over 2019-2021 and estimated to create US $0.69 billion opportunity in 2027 over 2021.

Aesthetic Centres

Aesthetic Centres segment was valued at US $0.78 billion in 2019 and is projected to grow at 5.16% CAGR over the forecast period to reach US $1.23 billion by 2027. Aesthetic Centres segment represented US $0.09 billion opportunity over 2019-2021 and estimated to create US $0.35 billion opportunity in 2027 over 2021.

Orthopedic Clinics

Orthopedic Clinics segment was valued at US $0.52 billion in 2019 and is projected to grow at 5.16% CAGR over the forecast period to reach US $0.82 billion by 2027. Orthopedic Clinics segment represented US $0.06 billion opportunity over 2019-2021 and estimated to create US $0.24 billion opportunity in 2027 over 2021.

Dental Clinics

Dental Clinics segment was valued at US $0.51 billion in 2019 and is projected to grow at 5.16% CAGR over the forecast period to reach US $0.80 billion by 2027. Dental Clinics segment represented US $0.06 billion opportunity over 2019-2021 and estimated to create US $0.23 billion opportunity in 2027 over 2021.

Other End Users

Other End Users segment was valued at US $0.20 billion in 2019 and is projected to grow at 5.16% CAGR over the forecast period to reach US $0.32 billion by 2027. Other End Users segment represented US $0.02 billion opportunity over 2019-2021 and estimated to create US $0.09 billion opportunity in 2027 over 2021.